Cas:13544-07-5 Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate manufacturer & supplier

We serve Chemical Name:Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate CAS:13544-07-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate

Chemical Name:Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate
CAS.NO:13544-07-5
Synonyms:methyl 2-[2-nitro-4-(trifluoromethyl)phenyl]acetate
Molecular Formula:C10H8F3NO4
Molecular Weight:263.17000
HS Code:2916399090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:277.7ºC at 760mmHg
Density:1.402g/cm3
Index of Refraction:1.484
PSA:72.12000
Exact Mass:263.04100
LogP:2.85230

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like methyl 2-[2-nitro-4-(trifluoromethyl)phenyl]acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 2-[2-nitro-4-(trifluoromethyl)phenyl]acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 2-[2-nitro-4-(trifluoromethyl)phenyl]acetate Use and application,methyl 2-[2-nitro-4-(trifluoromethyl)phenyl]acetate technical grade,usp/ep/jp grade.


Related News: At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves. Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate supplier As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate vendor The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s (EBS.N) plant for manufacturing the J&J vaccine. Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate factory The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s (EBS.N) plant for manufacturing the J&J vaccine.